Building personalized treatment plans for early-stage colorectal cancer patients-Reference-Cited by-同舟云学术

Building personalized treatment plans for early-stage colorectal cancer patients

Published:2017-01-13 Issue:8 Volume:8 Page:13805-13817
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Lin Hung-Hsin¹²,Wei Nien-Chih³,Chou Teh-Ying⁴⁵,Lin Chun-Chi¹²,Lan Yuan-Tsu¹²,Chang Shin-Ching¹²,Wang Huann-Sheng¹²,Yang Shung-Haur¹²,Chen Wei-Shone¹²,Lin Tzu-Chen¹²,Lin Jen-Kou¹²,Jiang Jeng-Kai¹²

Affiliation:

1. Division of Colon and Rectal Surgery, Department of Surgery, Taipei Veterans General Hospital, Taiwan

2. Department of Surgery, School of Medicine, National Yang-Ming University, Taiwan

3. Auspex Diagnostics, Taiwan

4. Division of Molecular Pathology, Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

5. Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant chemotherapy in stage 1 colon cancer: Patient characteristics and survival analysis from the national cancer database;Surgical Oncology;2024-06

2. Precision medicine-guided co-delivery of ASPN siRNA and oxaliplatin by nanoparticles to overcome chemoresistance of colorectal cancer;Biomaterials;2022-11

3. Molecular Subclassification Based on Crosstalk Analysis Improves Prediction of Prognosis in Colorectal Cancer;Frontiers in Genetics;2021-11-04

4. BAI1 as a Prognostic Marker of Clear Cell Renal Cell Carcinoma (ccRCC);Anticancer Research;2021-09

5. Suppression MGP inhibits tumor proliferation and reverses oxaliplatin resistance in colorectal cancer;Biochemical Pharmacology;2021-07